Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy
Coronavirus disease 2019 (COVID‐19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, poses a significant threat to public health. Angiotensin‐converting enzyme 2 (ACE2) is a key receptor for SARS‐CoV‐2 infection. Recombinant human ACE2 (RhACE2), as a solubl...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2023-11, Vol.95 (11), p.e29221-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | e29221 |
| container_title | Journal of medical virology |
| container_volume | 95 |
| creator | Wang, Zilei Zhao, Chuanke Li, Chuangui Liu, Song Ding, Jin He, Chengxue Liu, Jiayue Dong, Bin Yang, Zhi Liu, Qi Zhu, Hua Liu, Youping |
| description | Coronavirus disease 2019 (COVID‐19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, poses a significant threat to public health. Angiotensin‐converting enzyme 2 (ACE2) is a key receptor for SARS‐CoV‐2 infection. Recombinant human ACE2 (RhACE2), as a soluble supplement for human ACE2, can competitively block SARS‐CoV‐2 infection. In this study, a mouse organ in situ rhACE2 high aggregation model was constructed for the first time, and in vivo real‐time positron emission tomography (PET) imaging of rhACE2 in the mouse model was performed using an ACE2‐specific agent 68Ga‐HZ20. This radiotracer exhibits reliable radiochemical properties in vitro and maintains a high affinity for rhACE2 in vivo. In terms of probe uptake, 68Ga‐HZ20 showed a good target‐to‐nontarget ratio and was rapidly cleared from the circulatory system and excreted by the kidneys and urinary system. PET imaging with this radiotracer can noninvasively and accurately monitor the content and distribution of rhACE2 in the body, which clarifies that rhACE2 can aggregate in multiple organs, suggesting the preventive and therapeutic potential of rhACE2 for SARS‐CoV‐2 and COVID‐19. |
| doi_str_mv | 10.1002/jmv.29221 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2894723158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2894351311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-193c11ac99c4520b3bbbe271773d05e6131ba0ac5f2e1113ce9c91aba154c7793</originalsourceid><addsrcrecordid>eNp10UFP2zAUB3ALbYLCduALTJZ2GYdQP7tO6mMVdWMTaNPouEYvjlNcJXGwE6be-Ah8Rj7JTMs4TNrFlp5--tt6f0JOgZ0DY3y6ae_PueIcDsgEmEoTxTJ4QyYMZmmSpiCPyHEIG8bYPKpDciTmjKmMyQm5v3KN0WODnv5Yrqb5irbY97ZbU1dTf7vIl5xWNgzeluNgXUexq-jdiN1ga6txN7IddX6NXaCDo2ir58H14uf108Nj7m7iyemAfm0GU9Hh1njst-_I2xqbYN6_3Cfk1-flKr9ILr9_-ZovLhMtpIAElNAAqJXSM8lZKcqyNDyDLBMVkyYFASUy1LLmBgCENkorwBJBznSWKXFCPu1ze-_uRhOGorVBm6bBzrgxFHyuZhkXIOeRfvyHbtzou_i7nRIyPgZRne2V9i4Eb-qi97ZFvy2AFc9lFLGMYldGtB9eEseyNdWr_Lv9CKZ78Ns2Zvv_pOLb1c0-8g-jw5Oh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2894351311</pqid></control><display><type>article</type><title>Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wang, Zilei ; Zhao, Chuanke ; Li, Chuangui ; Liu, Song ; Ding, Jin ; He, Chengxue ; Liu, Jiayue ; Dong, Bin ; Yang, Zhi ; Liu, Qi ; Zhu, Hua ; Liu, Youping</creator><creatorcontrib>Wang, Zilei ; Zhao, Chuanke ; Li, Chuangui ; Liu, Song ; Ding, Jin ; He, Chengxue ; Liu, Jiayue ; Dong, Bin ; Yang, Zhi ; Liu, Qi ; Zhu, Hua ; Liu, Youping</creatorcontrib><description>Coronavirus disease 2019 (COVID‐19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, poses a significant threat to public health. Angiotensin‐converting enzyme 2 (ACE2) is a key receptor for SARS‐CoV‐2 infection. Recombinant human ACE2 (RhACE2), as a soluble supplement for human ACE2, can competitively block SARS‐CoV‐2 infection. In this study, a mouse organ in situ rhACE2 high aggregation model was constructed for the first time, and in vivo real‐time positron emission tomography (PET) imaging of rhACE2 in the mouse model was performed using an ACE2‐specific agent 68Ga‐HZ20. This radiotracer exhibits reliable radiochemical properties in vitro and maintains a high affinity for rhACE2 in vivo. In terms of probe uptake, 68Ga‐HZ20 showed a good target‐to‐nontarget ratio and was rapidly cleared from the circulatory system and excreted by the kidneys and urinary system. PET imaging with this radiotracer can noninvasively and accurately monitor the content and distribution of rhACE2 in the body, which clarifies that rhACE2 can aggregate in multiple organs, suggesting the preventive and therapeutic potential of rhACE2 for SARS‐CoV‐2 and COVID‐19.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.29221</identifier><identifier>PMID: 38009705</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>68Ga‐HZ20 ; ACE2 ; Angiotensin ; Angiotensin-Converting Enzyme 2 ; Animals ; Circulatory system ; Coronaviruses ; COVID-19 ; COVID-19 - diagnostic imaging ; Disease Models, Animal ; Health risks ; Humans ; Infections ; Kidneys ; Medical imaging ; Mice ; Organs ; Peptidyl-Dipeptidase A ; PET imaging ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Public health ; Radioactive tracers ; Radiochemistry ; Respiratory diseases ; rhACE2‐organ model ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases ; Virology</subject><ispartof>Journal of medical virology, 2023-11, Vol.95 (11), p.e29221-n/a</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-193c11ac99c4520b3bbbe271773d05e6131ba0ac5f2e1113ce9c91aba154c7793</citedby><cites>FETCH-LOGICAL-c3531-193c11ac99c4520b3bbbe271773d05e6131ba0ac5f2e1113ce9c91aba154c7793</cites><orcidid>0000-0002-3285-7864</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.29221$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.29221$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38009705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Zilei</creatorcontrib><creatorcontrib>Zhao, Chuanke</creatorcontrib><creatorcontrib>Li, Chuangui</creatorcontrib><creatorcontrib>Liu, Song</creatorcontrib><creatorcontrib>Ding, Jin</creatorcontrib><creatorcontrib>He, Chengxue</creatorcontrib><creatorcontrib>Liu, Jiayue</creatorcontrib><creatorcontrib>Dong, Bin</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Liu, Qi</creatorcontrib><creatorcontrib>Zhu, Hua</creatorcontrib><creatorcontrib>Liu, Youping</creatorcontrib><title>Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>Coronavirus disease 2019 (COVID‐19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, poses a significant threat to public health. Angiotensin‐converting enzyme 2 (ACE2) is a key receptor for SARS‐CoV‐2 infection. Recombinant human ACE2 (RhACE2), as a soluble supplement for human ACE2, can competitively block SARS‐CoV‐2 infection. In this study, a mouse organ in situ rhACE2 high aggregation model was constructed for the first time, and in vivo real‐time positron emission tomography (PET) imaging of rhACE2 in the mouse model was performed using an ACE2‐specific agent 68Ga‐HZ20. This radiotracer exhibits reliable radiochemical properties in vitro and maintains a high affinity for rhACE2 in vivo. In terms of probe uptake, 68Ga‐HZ20 showed a good target‐to‐nontarget ratio and was rapidly cleared from the circulatory system and excreted by the kidneys and urinary system. PET imaging with this radiotracer can noninvasively and accurately monitor the content and distribution of rhACE2 in the body, which clarifies that rhACE2 can aggregate in multiple organs, suggesting the preventive and therapeutic potential of rhACE2 for SARS‐CoV‐2 and COVID‐19.</description><subject>68Ga‐HZ20</subject><subject>ACE2</subject><subject>Angiotensin</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Animals</subject><subject>Circulatory system</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnostic imaging</subject><subject>Disease Models, Animal</subject><subject>Health risks</subject><subject>Humans</subject><subject>Infections</subject><subject>Kidneys</subject><subject>Medical imaging</subject><subject>Mice</subject><subject>Organs</subject><subject>Peptidyl-Dipeptidase A</subject><subject>PET imaging</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Public health</subject><subject>Radioactive tracers</subject><subject>Radiochemistry</subject><subject>Respiratory diseases</subject><subject>rhACE2‐organ model</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10UFP2zAUB3ALbYLCduALTJZ2GYdQP7tO6mMVdWMTaNPouEYvjlNcJXGwE6be-Ah8Rj7JTMs4TNrFlp5--tt6f0JOgZ0DY3y6ae_PueIcDsgEmEoTxTJ4QyYMZmmSpiCPyHEIG8bYPKpDciTmjKmMyQm5v3KN0WODnv5Yrqb5irbY97ZbU1dTf7vIl5xWNgzeluNgXUexq-jdiN1ga6txN7IddX6NXaCDo2ir58H14uf108Nj7m7iyemAfm0GU9Hh1njst-_I2xqbYN6_3Cfk1-flKr9ILr9_-ZovLhMtpIAElNAAqJXSM8lZKcqyNDyDLBMVkyYFASUy1LLmBgCENkorwBJBznSWKXFCPu1ze-_uRhOGorVBm6bBzrgxFHyuZhkXIOeRfvyHbtzou_i7nRIyPgZRne2V9i4Eb-qi97ZFvy2AFc9lFLGMYldGtB9eEseyNdWr_Lv9CKZ78Ns2Zvv_pOLb1c0-8g-jw5Oh</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Wang, Zilei</creator><creator>Zhao, Chuanke</creator><creator>Li, Chuangui</creator><creator>Liu, Song</creator><creator>Ding, Jin</creator><creator>He, Chengxue</creator><creator>Liu, Jiayue</creator><creator>Dong, Bin</creator><creator>Yang, Zhi</creator><creator>Liu, Qi</creator><creator>Zhu, Hua</creator><creator>Liu, Youping</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3285-7864</orcidid></search><sort><creationdate>202311</creationdate><title>Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy</title><author>Wang, Zilei ; Zhao, Chuanke ; Li, Chuangui ; Liu, Song ; Ding, Jin ; He, Chengxue ; Liu, Jiayue ; Dong, Bin ; Yang, Zhi ; Liu, Qi ; Zhu, Hua ; Liu, Youping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-193c11ac99c4520b3bbbe271773d05e6131ba0ac5f2e1113ce9c91aba154c7793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>68Ga‐HZ20</topic><topic>ACE2</topic><topic>Angiotensin</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Animals</topic><topic>Circulatory system</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnostic imaging</topic><topic>Disease Models, Animal</topic><topic>Health risks</topic><topic>Humans</topic><topic>Infections</topic><topic>Kidneys</topic><topic>Medical imaging</topic><topic>Mice</topic><topic>Organs</topic><topic>Peptidyl-Dipeptidase A</topic><topic>PET imaging</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Public health</topic><topic>Radioactive tracers</topic><topic>Radiochemistry</topic><topic>Respiratory diseases</topic><topic>rhACE2‐organ model</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Zilei</creatorcontrib><creatorcontrib>Zhao, Chuanke</creatorcontrib><creatorcontrib>Li, Chuangui</creatorcontrib><creatorcontrib>Liu, Song</creatorcontrib><creatorcontrib>Ding, Jin</creatorcontrib><creatorcontrib>He, Chengxue</creatorcontrib><creatorcontrib>Liu, Jiayue</creatorcontrib><creatorcontrib>Dong, Bin</creatorcontrib><creatorcontrib>Yang, Zhi</creatorcontrib><creatorcontrib>Liu, Qi</creatorcontrib><creatorcontrib>Zhu, Hua</creatorcontrib><creatorcontrib>Liu, Youping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Zilei</au><au>Zhao, Chuanke</au><au>Li, Chuangui</au><au>Liu, Song</au><au>Ding, Jin</au><au>He, Chengxue</au><au>Liu, Jiayue</au><au>Dong, Bin</au><au>Yang, Zhi</au><au>Liu, Qi</au><au>Zhu, Hua</au><au>Liu, Youping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-11</date><risdate>2023</risdate><volume>95</volume><issue>11</issue><spage>e29221</spage><epage>n/a</epage><pages>e29221-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>Coronavirus disease 2019 (COVID‐19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, poses a significant threat to public health. Angiotensin‐converting enzyme 2 (ACE2) is a key receptor for SARS‐CoV‐2 infection. Recombinant human ACE2 (RhACE2), as a soluble supplement for human ACE2, can competitively block SARS‐CoV‐2 infection. In this study, a mouse organ in situ rhACE2 high aggregation model was constructed for the first time, and in vivo real‐time positron emission tomography (PET) imaging of rhACE2 in the mouse model was performed using an ACE2‐specific agent 68Ga‐HZ20. This radiotracer exhibits reliable radiochemical properties in vitro and maintains a high affinity for rhACE2 in vivo. In terms of probe uptake, 68Ga‐HZ20 showed a good target‐to‐nontarget ratio and was rapidly cleared from the circulatory system and excreted by the kidneys and urinary system. PET imaging with this radiotracer can noninvasively and accurately monitor the content and distribution of rhACE2 in the body, which clarifies that rhACE2 can aggregate in multiple organs, suggesting the preventive and therapeutic potential of rhACE2 for SARS‐CoV‐2 and COVID‐19.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38009705</pmid><doi>10.1002/jmv.29221</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3285-7864</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2023-11, Vol.95 (11), p.e29221-n/a |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2894723158 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | 68Ga‐HZ20 ACE2 Angiotensin Angiotensin-Converting Enzyme 2 Animals Circulatory system Coronaviruses COVID-19 COVID-19 - diagnostic imaging Disease Models, Animal Health risks Humans Infections Kidneys Medical imaging Mice Organs Peptidyl-Dipeptidase A PET imaging Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Public health Radioactive tracers Radiochemistry Respiratory diseases rhACE2‐organ model SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases Virology |
| title | Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to aid in SARS‐CoV‐2 targeted therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A57%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20PET/CT%20mapping%20of%20rhACE2%20distribution%20and%20quantification%20in%20organs%20to%20aid%20in%20SARS%E2%80%90CoV%E2%80%902%20targeted%20therapy&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Wang,%20Zilei&rft.date=2023-11&rft.volume=95&rft.issue=11&rft.spage=e29221&rft.epage=n/a&rft.pages=e29221-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.29221&rft_dat=%3Cproquest_cross%3E2894351311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2894351311&rft_id=info:pmid/38009705&rfr_iscdi=true |